PPARs激动剂对RAW264.7巨噬细胞源性泡沫细胞内胆固醇含量的影响

The effects of PPARs agonist on cholesterol levels in RAW264.7 macrophage-derived foam cell

目的 探讨PPARs激动剂吡格列酮对RAW264.7巨噬细胞源性泡沫细胞内胆固醇含量的影响.方法 首先用50 mg/L氧化型低密度脂蛋白（ox-LDL）将体外培养的RAW264.7巨噬细胞诱导分化为泡沫细胞,然后进行油红O染色,并在光镜下鉴定泡沫细胞形态及变化;再以不同浓度吡格列酮（0 μmol/L、5 μmol/L、10μmol/L、20 μmol/L、30 μmol/L）作用泡沫细胞24h,以30 μmol/L的吡格列酮作用0h、6h、12h、24 h、48 h;最后酶法检测泡沫细胞内胆固醇的含量.结果 ①50 mg/Lox-LDL诱导巨噬细胞48 h后分化为泡沫细胞.②与对照组相比,不同浓度吡格列酮作用后泡沫细胞内胆固醇含量均减少,差异有统计学意义（P＜0.01）,且呈剂量依赖性.③与对照组相比,30 μmol/L的吡格列酮作用6h、12 h、24 h、48 h后,泡沫细胞内胆固醇含量均减少,差异有统计学意义（P＜0.01）,且呈时间依赖性.结论 PPARs激动剂吡格列酮能够减少泡沫细胞内胆固醇含量,且呈剂量和时间依赖性。

Objective To observe the effects of PPARs agonist Pioglitazone on cholesterol levels in RAW264.7 macrophage-derived foam cell. Methods Firstly, with 50 mg/L oxidized low density lipoprotein （ox- LDL） induce the mouse RAW264.7 cells into foam cells. Secondly, using red oil O staining technique and transmission light microscope was applied to appraise the morphology and change of foam cells. Thirdly, Pioglitazone of different concentrations （0 μmol/L, 5 μmol/L, 10 μmol/L, 20 μmol/L, 30 μmol/L） were incubated with RAW264.7 macrophage-derived foam cell for 24 h and 20 μmol/L pioglitazone were incubated with RAW264.7 macrophage-derived foam cell for 6 h, 12 h, 24 h, d8 h. Lastly, the cholesterol content of foam cells was measured by enzyme assay. Results （1）The mouse RAW264.7 cells could be differentiated into macrophages after 48h induction by 50 mg/L oxidized low density lipoprotein （ox-LDL）. （2）Compared with the control group, treatment of RAW264.7 macrophage-derived foam cell with 5 μmol/L, 10 μmol/L, 20 p,mol/L, 30 p.mol/L pioglitazone for 24 h, resulted in an decrease in the cholesterol content of foam ceils, differences are statistically significant（P〈0.01 ）.（3）Compared with the control group, treatment of RAW264.7 macrophage-derived foam cell with 20 μmol/L pioglitazone for 6 h, 12 h, 24 h, 48 h, resuhed in a decrease in the cholesterol content of foam cells, differences were statistically significant （P〈0.01）. Conclusion PPARs agonist pioglitazone reduces cholesterol levels in foam cells in dose and time dependent.